



Veracyte, Inc.
Investor Relations Department
6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VCYT

Last Trade:	7.82
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	-0.23 (-2.857%)
Day Range	7.75 - 8.20
52-Week Range	5.20 - 9.71
Volume	163,454

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 31, 2017

[Veracyte Announces Second Quarter 2017 Financial Results](#)

Jul 31, 2017

[Veracyte Announces Pivotal Clinical Validation Data for Afirma Genomic Sequencing Classifier Presented at World Congress on Thyroid Cancer](#)

Jul 26, 2017

[Veracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer](#)

Jul 18, 2017

[Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017](#)

Jun 27, 2017

[Veracyte Announces Publication of Study Supporting the Development of Envisia™ Genomic Classifier for IPF in Annals of the American Thoracic Society](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Jul 31, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)